Literature DB >> 25675386

Adolescent polycystic ovary syndrome due to functional ovarian hyperandrogenism persists into adulthood.

Robert L Rosenfield1, David A Ehrmann, Elizabeth E Littlejohn.   

Abstract

BACKGROUND: Menstrual irregularity and above-average testosterone levels in adolescence may presage polycystic ovary syndrome (PCOS) in adulthood but persist in only a minority. Prolonged anovulatory cycles in normal adolescents are associated with increased testosterone levels. Thus, questions have been raised about the accuracy of PCOS diagnosed in adolescents.
OBJECTIVE: The purpose of this study was to follow-up hyperandrogenic adolescents with features of PCOS to test the hypothesis that adolescent functional ovarian hyperandrogenism (FOH) persists into adulthood. STUDY
SUBJECTS: A series of adults previously reported to have adolescent PCOS, with most documented to have FOH by GnRH agonist or dexamethasone androgen-suppression test criteria, were recalled.
METHODS: Recall occurred >3 years after the initial diagnosis and at the age of >18.0 years. Respondents underwent examination, baseline androgen evaluation, and an oral glucose tolerance test after discontinuing oral contraceptive therapy.
RESULTS: Of the adolescent hyperandrogenic patients, 68% (15 of 22) were traceable, and 60% of those traced returned for follow-up, including half (n = 8) of the original FOH group. The baseline characteristics of respondents and nonrespondents were not significantly different. Patients with FOH were reevaluated when their mean age was 23.0 years (range, 18.4-29.4 years), gynecologic age was 10.7 years (range, 5.5-18.4 years), and body mass index was 42.3 kg/m(2) (range, 28.3-52.1 kg/m(2); P = .02 vs adolescence). Serum free testosterone was 24 pg/mL (range, 10-38 pg/mL, normal, 3-9 pg/mL; not significant vs adolescence); all were oligomenorrheic. Whereas 3 of 8 had impaired glucose tolerance as adolescents, at follow-up 6 of 8 had developed abnormal glucose tolerance (2 with type 2 diabetes mellitus).
CONCLUSIONS: Adolescents with FOH, which underlies most PCOS, uniformly have persistent hyperandrogenism, and glucose tolerance tends to deteriorate. Testing ovarian androgenic function in hyperandrogenic adolescents may be of prognostic value.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25675386      PMCID: PMC4399308          DOI: 10.1210/jc.2014-4290

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  31 in total

1.  Diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

2.  Endocrine determinants of fertility: serum androgen concentrations during follow-up of adolescents into the third decade of life.

Authors:  D Apter; R Vihko
Journal:  J Clin Endocrinol Metab       Date:  1990-10       Impact factor: 5.958

3.  Follicular growth in relation to serum hormonal patterns in adolescent compared with adult menstrual cycles.

Authors:  D Apter; I Räisänen; P Ylöstalo; R Vihko
Journal:  Fertil Steril       Date:  1987-01       Impact factor: 7.329

4.  Circadian variations of luteinizing hormone can have two different profiles in adolescent anovulation.

Authors:  E Porcu; S Venturoli; O Magrini; R Bolzani; D Gabbi; R Paradisi; R Fabbri; C Flamigni
Journal:  J Clin Endocrinol Metab       Date:  1987-09       Impact factor: 5.958

5.  The prognosis for adolescents with menstrual abnormalities.

Authors:  A L Southam; R M Richart
Journal:  Am J Obstet Gynecol       Date:  1966-03-01       Impact factor: 8.661

6.  Diagnosis of the polycystic ovary syndrome in adolescence: comparison of adolescent and adult hyperandrogenism.

Authors:  R L Rosenfield; K Ghai; D A Ehrmann; R B Barnes
Journal:  J Pediatr Endocrinol Metab       Date:  2000       Impact factor: 1.634

7.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

8.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.

Authors: 
Journal:  Fertil Steril       Date:  2004-01       Impact factor: 7.329

9.  Menstrual irregularities in adolescents: hormonal pattern and ovarian morphology.

Authors:  S Venturoli; E Porcu; R Fabbri; R Paradisi; S Ruggeri; G Bolelli; L F Orsini; D Gabbi; C Flamigni
Journal:  Horm Res       Date:  1986

10.  Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years.

Authors:  M H A van Hooff; F J Voorhorst; M B H Kaptein; R A Hirasing; C Koppenaal; J Schoemaker
Journal:  Hum Reprod       Date:  2004-02       Impact factor: 6.918

View more
  5 in total

1.  Current concepts of polycystic ovary syndrome pathogenesis.

Authors:  Robert L Rosenfield
Journal:  Curr Opin Pediatr       Date:  2020-10       Impact factor: 2.856

Review 2.  Development of Ovulatory Menstrual Cycles in Adolescent Girls.

Authors:  Lauren J Carlson; Natalie D Shaw
Journal:  J Pediatr Adolesc Gynecol       Date:  2019-02-14       Impact factor: 1.814

3.  American, European, and Chinese practice guidelines or consensuses of polycystic ovary syndrome: a comparative analysis.

Authors:  Fang-Fang Wang; Jie-Xue Pan; Yan Wu; Yu-Hang Zhu; Paul J Hardiman; Fan Qu
Journal:  J Zhejiang Univ Sci B       Date:  2018-05       Impact factor: 3.066

4.  Correlation of Clinical, Hormonal, Biochemical and Ultrasound Parameters Between Adult and Adolescent Polycystic Ovarian Syndrome: Adult and Adolescent PCOS.

Authors:  Shivi Jain; Madhu Jain; R C Shukla
Journal:  J Obstet Gynaecol India       Date:  2021-10-09

Review 5.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.